Ionis Pharmaceuticals Files 8-K
Ticker: IONS · Form: 8-K · Filed: Aug 1, 2024 · CIK: 874015
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
IONIS filed an 8-K on Aug 1st detailing financials. Check it out.
AI Summary
Ionis Pharmaceuticals, Inc. filed an 8-K on August 1, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 2855 Gazelle Court, Carlsbad, CA 92010. Ionis Pharmaceuticals was formerly known as Isis Pharmaceuticals Inc. until a name change on March 28, 1993.
Why It Matters
This 8-K filing provides an update on Ionis Pharmaceuticals' financial status and operational results, which is crucial information for investors and stakeholders to assess the company's performance.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and does not indicate any unusual or high-risk events.
Key Players & Entities
- IONIS PHARMACEUTICALS INC (company) — Filer
- August 1, 2024 (date) — Report Date
- 2855 Gazelle Court Carlsbad, CA 92010 (location) — Principal Executive Offices
- Isis Pharmaceuticals Inc. (company) — Former Company Name
- March 28, 1993 (date) — Date of Name Change
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Ionis Pharmaceuticals, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this report filed?
This report was filed on August 1, 2024.
What is the principal business address of Ionis Pharmaceuticals, Inc.?
The principal business address is 2855 Gazelle Court, Carlsbad, CA 92010.
Has Ionis Pharmaceuticals, Inc. always been known by this name?
No, the company was formerly known as Isis Pharmaceuticals Inc. until a name change on March 28, 1993.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 609 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-08-01 11:15:31
Filing Documents
- ef20033414_8k.htm (8-K) — 26KB
- ef20033414_ex99-1.htm (EX-99.1) — 382KB
- image0.jpg (GRAPHIC) — 24KB
- image1.jpg (GRAPHIC) — 1KB
- 0001140361-24-035233.txt ( ) — 600KB
- ions-20240801.xsd (EX-101.SCH) — 4KB
- ions-20240801_lab.xml (EX-101.LAB) — 21KB
- ions-20240801_pre.xml (EX-101.PRE) — 16KB
- ef20033414_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On August 1, 2024, Ionis Pharmaceuticals, Inc. (the " Company ") issued a press release announcing the Company's financial results for the quarter ended June 30, 2024. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (" GAAP "), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. The Company is presenting pro forma information excluding non-cash compensation expense and the related tax effects because the Company believes it better enables financial statement users to assess and compare its historical performance and project its future operating results and cash flows. A copy of the release is furnished with this report as an exhibit pursuant to "Item 2.02. Results of Operations and Financial Condition" of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583. The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the " Exchange Act ") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated August 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Ionis Pharmaceuticals, Inc. Dated: August 1, 2024 By: /s/ Patrick R. O'Neil Patrick R. O'Neil Executive Vice President, Chief Legal Officer and General Counsel